US2022265796A1PendingUtilityA1

Chimeric antigen receptors targeting her2

68
Assignee: HOPE CITYPriority: Nov 4, 2015Filed: Dec 6, 2021Published: Aug 25, 2022
Est. expiryNov 4, 2035(~9.3 yrs left)· nominal 20-yr term from priority
Inventors:Saul J. PricemanStephen J. FormanChristine E. Brown
A61K 40/31A61K 40/11A61K 40/4205A61K 40/50C07K 2319/03A61P 35/00A61K 2039/505C12N 15/86C12N 15/85C07K 2319/33C12N 2830/15C07K 14/71C07K 14/7051C07K 2317/71C07K 14/70503C07K 2317/524C07K 16/32C07K 14/70521C07K 2317/622C07K 16/2863C12N 2740/16043A61K 35/17C12N 5/0636A61K 39/001106A61K 2239/31A61K 2239/47A61K 2239/17A61K 2239/22A61K 2239/21C07K 2319/02A61P 35/04C07K 14/70517C07K 14/70514C12N 2510/00A61K 35/12C07K 14/70578C07K 2319/74A61K 2039/812A61K 2039/80
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain targeted to HER2, a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.

Claims

exact text as granted — not AI-modified
1 .- 32 . (canceled) 
     
     
         33 . A chimeric antigen receptor (CAR) comprising an amino acid sequence selected from any one of SEQ ID NOs: 26-41. 
     
     
         34 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 26. 
     
     
         35 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 27. 
     
     
         35 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 28. 
     
     
         37 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 29. 
     
     
         38 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 30. 
     
     
         39 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 31. 
     
     
         40 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 32. 
     
     
         41 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 33. 
     
     
         42 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 34. 
     
     
         43 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 35. 
     
     
         44 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 36. 
     
     
         45 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 37. 
     
     
         46 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 38. 
     
     
         47 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 39. 
     
     
         48 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 40. 
     
     
         49 . The CAR of  claim 33 , wherein the CAR comprises SEQ ID NO: 41. 
     
     
         50 . A method of treating a HER2 expressing cancer in a patient comprising administering a population of autologous or allogeneic human T cells expressing a chimeric antigen receptor, wherein chimeric antigen receptor comprises an amino acid sequence selected from any one of SEQ ID NOs: 34-41. 
     
     
         51 . The method of  claim 50 , wherein the population of human T cells comprise CD62L+ memory T cells. 
     
     
         52 . The method  claim 50 , wherein the cancer is a breast to brain metastasis. 
     
     
         53 . The method of  claim 52 , wherein the T cells are administered intratumorally. 
     
     
         54 . The method of  claim 52 , wherein the T cells are administered intraventricularly. 
     
     
         55 . The method of  claim 52 , wherein the T cells are administered intravetricularly adjacent to a tumor.

Join the waitlist — get patent alerts

Track US2022265796A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.